Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLX NASDAQ:CMPS NASDAQ:STOK NASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$18.27+1.8%$15.16$5.97▼$19.15$2.00B-0.21.86 million shs1.39 million shsCMPSCompass Pathways$13.62+2.5%$11.46$3.24▼$15.40$1.79B2.473.14 million shs4.10 million shsSTOKStoke Therapeutics$32.700.0%$31.23$11.36▼$40.22$2.04B1.17974,793 shs1.01 million shsSTROSutro Biopharma$30.43+0.6%$31.65$7.15▼$43.85$501.09M1.51403,889 shs524,926 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+0.02%+5.59%+27.58%+20.07%+180.03%CMPSCompass Pathways-6.08%+5.77%-6.34%+129.53%+320.57%STOKStoke Therapeutics-0.03%+7.60%+7.35%-0.09%+180.77%STROSutro Biopharma-8.92%+0.73%+7.04%+27.17%+344.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$18.27+1.8%$15.16$5.97▼$19.15$2.00B-0.21.86 million shs1.39 million shsCMPSCompass Pathways$13.62+2.5%$11.46$3.24▼$15.40$1.79B2.473.14 million shs4.10 million shsSTOKStoke Therapeutics$32.700.0%$31.23$11.36▼$40.22$2.04B1.17974,793 shs1.01 million shsSTROSutro Biopharma$30.43+0.6%$31.65$7.15▼$43.85$501.09M1.51403,889 shs524,926 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+0.02%+5.59%+27.58%+20.07%+180.03%CMPSCompass Pathways-6.08%+5.77%-6.34%+129.53%+320.57%STOKStoke Therapeutics-0.03%+7.60%+7.35%-0.09%+180.77%STROSutro Biopharma-8.92%+0.73%+7.04%+27.17%+344.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 2.90Moderate Buy$24.2532.73% UpsideCMPSCompass Pathways 3.00Buy$23.1069.60% UpsideSTOKStoke Therapeutics 2.73Moderate Buy$41.8327.93% UpsideSTROSutro Biopharma 2.92Moderate Buy$52.4472.34% UpsideCurrent Analyst Ratings BreakdownLatest STRO, CMPS, STOK, and AMLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2026CMPSCompass Pathways Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.006/25/2026AMLXAmylyx Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $40.006/11/2026STROSutro Biopharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.006/8/2026AMLXAmylyx Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.006/1/2026CMPSCompass Pathways TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/28/2026STROSutro Biopharma BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$56.005/28/2026STROSutro Biopharma BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$56.005/22/2026CMPSCompass Pathways Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026CMPSCompass Pathways HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026CMPSCompass Pathways Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/15/2026CMPSCompass Pathways Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $20.00(Data available from 7/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M23.25N/AN/A$2.78 per share6.57CMPSCompass PathwaysN/AN/AN/AN/A($0.55) per shareN/ASTOKStoke Therapeutics$184.42M11.04N/AN/A$6.17 per share5.30STROSutro Biopharma$102.48M4.92N/AN/A($15.43) per share-1.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals-$144.74M-$1.50N/AN/AN/AN/A-55.69%-50.73%8/6/2026 (Estimated)CMPSCompass Pathways-$287.86M-$3.15N/AN/AN/AN/A-31.07%-11.40%7/30/2026 (Estimated)STOKStoke Therapeutics-$6.89M-$2.81N/AN/AN/A-529.20%-48.84%-42.27%8/11/2026 (Estimated)STROSutro Biopharma-$191.09M-$11.04N/AN/AN/A-154.21%N/A-69.20%8/6/2026 (Estimated)Latest STRO, CMPS, STOK, and AMLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2026Q2 2026CMPSCompass Pathways-$0.3857N/AN/AN/AN/AN/A5/14/2026Q1 2026STROSutro Biopharma-$2.7363-$2.94-$0.2037-$2.94$8.89 million$14.52 million5/13/2026Q1 2026CMPSCompass Pathways-$0.45-$0.30+$0.15-$0.30N/AN/A5/7/2026Q1 2026AMLXAmylyx Pharmaceuticals-$0.34-$0.37-$0.03-$0.37N/AN/A5/7/2026Q1 2026STOKStoke Therapeutics-$0.80-$0.79+$0.01-$0.79$6.48 million$6.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/ACMPSCompass PathwaysN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A17.8517.85CMPSCompass Pathways0.153.323.32STOKStoke TherapeuticsN/A8.998.99STROSutro BiopharmaN/A3.123.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%CMPSCompass Pathways46.19%STOKStoke TherapeuticsN/ASTROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals10.90%CMPSCompass Pathways2.82%STOKStoke Therapeutics9.50%STROSutro Biopharma3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals200111.19 million99.07 millionOptionableCMPSCompass Pathways120134.95 million131.14 millionOptionableSTOKStoke Therapeutics10062.28 million56.37 millionOptionableSTROSutro Biopharma24016.57 million15.97 millionOptionableSTRO, CMPS, STOK, and AMLX HeadlinesRecent News About These CompaniesSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Moderate Buy" by AnalystsJune 26, 2026 | americanbankingnews.comNews Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) ForecastsMay 28, 2026 | finance.yahoo.comUS$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These ResultsMay 17, 2026 | finance.yahoo.comWedbush upgrades Sutro Biopharma (STRO)May 16, 2026 | msn.comSutro Biopharma Reports First Quarter 2026 Financial Results and Business HighlightsMay 14, 2026 | globenewswire.comCitizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead ProgramMay 1, 2026 | insidermonkey.comMizuho initiates coverage of Sutro Biopharma (STRO) with outperform recommendationMay 1, 2026 | msn.comSutro Biopharma: Recycling Past Data Ahead Of The Readout, SellMay 1, 2026 | seekingalpha.comHere is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right NowApril 29, 2026 | finance.yahoo.comSutro Biopharma, Inc. (STRO) Presents at AACR Annual Meeting 2026 - SlideshowApril 24, 2026 | seekingalpha.comSutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026April 19, 2026 | markets.businessinsider.comSutro Biopharma Reports Promising Preclinical Data for Next-Generation ADCs STRO-004, STRO-006, and STRO-227 at AACR Annual Meeting 2026April 19, 2026 | quiverquant.comQSutro Biopharma (NASDAQ:STRO) Trading 10.4% Higher on Analyst UpgradeApril 18, 2026 | defenseworld.netDSutro Biopharma (STRO) price target decreased by 21.62% to 29.58April 9, 2026 | msn.comSutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?April 8, 2026 | zacks.comLeerink Partners initiates coverage of Sutro Biopharma (STRO) with outperform recommendationApril 8, 2026 | msn.comSutro Biopharma (STRO) price target increased by 13.85% to 37.74March 27, 2026 | msn.comWells Fargo upgrades Sutro Biopharma (STRO)March 25, 2026 | msn.comHC Wainwright & Co. upgrades Sutro Biopharma (STRO)March 25, 2026 | msn.comSutro Biopharma Reports Full Year 2025 Financial Results and Business HighlightsMarch 23, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 AI Stocks With Moats That Could Outlast Summer VolatilityBy Chris Markoch | June 16, 20263 Stocks With Fresh Catalysts to Watch Before July 4By Chris Markoch | June 8, 2026Buy CrowdStrike Before the Stock Split? Here's the CaseBy Chris Markoch | June 22, 2026Time to Sell? 3 Winners With Fading Technical MomentumBy Dan Schmidt | June 13, 2026Everpure: AI Storage Uncertainty Overshadows Breakneck GrowthBy Leo Miller | June 10, 2026STRO, CMPS, STOK, and AMLX Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$18.27 +0.32 (+1.78%) Closing price 04:00 PM EasternExtended Trading$18.30 +0.03 (+0.14%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Compass Pathways NASDAQ:CMPS$13.62 +0.33 (+2.48%) Closing price 04:00 PM EasternExtended Trading$13.78 +0.16 (+1.16%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Stoke Therapeutics NASDAQ:STOK$32.70 -0.01 (-0.03%) Closing price 04:00 PM EasternExtended Trading$32.68 -0.02 (-0.06%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Sutro Biopharma NASDAQ:STRO$30.43 +0.19 (+0.63%) Closing price 04:00 PM EasternExtended Trading$31.16 +0.73 (+2.42%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Shorting the Grid: Bloom Energy’s $25B AI Power Play SMRs Spark a Chain Reaction for Nano Nuclear 3 Dividend ETFs Built for Stability in a Volatile Market Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AI Netflix Stock Is Near 2021 Levels, and Bulls See 4 Reasons to Care General Mills Is a 5-Star Turnaround Play for Buy and Hold Investors Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
